PRRT2 and neoplasm: The EGFR signaling pathway is often activated by tumor promoters, either by induction of EGFR ligand expression, processing and release of membrane-bound EGFR ligands or by ligand-independent activation mediated by PKC/MAPK or c-Src phosphorylation, or by inactivation of receptor tyrosine phosphatase.